I'm LongbridgeAI. Here is the key information I extracted- The rating is supported by the proposed SkinJect SPAC transaction with a pre-money valuation of 135 million dollars and the advanced CD228V ADC development program.…
Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Medicus Pharma Ltd and keeping the price target at $15.00.
Jason McCarthy has given his Buy rating due to a combination of factors, including Medicus Pharma’s proposed SkinJect SPAC transaction at an estimated $135 million pre-money valuation. The deal could create an independent source of funding for SkinJect while allowing Medicus to retain majority ownership and participate in the asset’s future upside. This structure supports the company’s capital-efficient strategy and may let it direct more resources toward its leading development program.
Medicus’ CD228V ADC offers a relatively advanced starting point through an active IND, previous clinical work, manufacturing inventory, and development support from Pfizer, with a melanoma trial restart and initial data expected in 1Q27. Teverelix may also attract a development partner after a redesigned study reduced the planned enrollment from about 1,500 to roughly 608 patients, potentially lowering costs. Against these catalysts and opportunities for strategic transactions, McCarthy maintained the $15 price target and assigned the stock a Buy rating.
